- Home
- ATLC vs TRVI Comparison
ATLC vs TRVI Comparison
Compare ATLC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- TRVI
- Stock Information
- Founded
- ATLC 1996
- TRVI 2011
- Country
- ATLC United States
- TRVI United States
- Employees
- ATLC N/A
- TRVI N/A
- Industry
- ATLC Finance: Consumer Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ATLC Finance
- TRVI Health Care
- Exchange
- ATLC Nasdaq
- TRVI Nasdaq
- Market Cap
- ATLC 900.3M
- TRVI 725.7M
- IPO Year
- ATLC 1999
- TRVI 2019
- Fundamental
- Price
- ATLC $61.35
- TRVI $7.52
- Analyst Decision
- ATLC Buy
- TRVI Strong Buy
- Analyst Count
- ATLC 7
- TRVI 9
- Target Price
- ATLC $66.14
- TRVI $19.50
- AVG Volume (30 Days)
- ATLC 45.4K
- TRVI 1.7M
- Earning Date
- ATLC 08-07-2025
- TRVI 08-07-2025
- Dividend Yield
- ATLC N/A
- TRVI N/A
- EPS Growth
- ATLC 35.13
- TRVI N/A
- EPS
- ATLC 5.69
- TRVI N/A
- Revenue
- ATLC $457,158,000.00
- TRVI N/A
- Revenue This Year
- ATLC $274.30
- TRVI N/A
- Revenue Next Year
- ATLC $12.69
- TRVI N/A
- P/E Ratio
- ATLC $10.78
- TRVI N/A
- Revenue Growth
- ATLC 26.20
- TRVI N/A
- 52 Week Low
- ATLC $30.00
- TRVI $2.36
- 52 Week High
- ATLC $64.70
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- ATLC 70.20
- TRVI 59.76
- Support Level
- ATLC $49.05
- TRVI $6.55
- Resistance Level
- ATLC $62.86
- TRVI $7.66
- Average True Range (ATR)
- ATLC 2.28
- TRVI 0.36
- MACD
- ATLC 1.44
- TRVI -0.04
- Stochastic Oscillator
- ATLC 89.07
- TRVI 81.51
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.